SLC16A6

Chr 17

solute carrier family 16 member 6

Also known as: MCT6, MCT7

The protein functions as a monocarboxylate transporter that selectively transports taurine across the plasma membrane in a pH- and sodium-independent manner, with particular effectiveness in tissues with high taurine concentrations. Mutations in SLC16A6 are predicted to cause disease through a gain-of-function mechanism, though specific associated neurological disorders have not yet been definitively established. The gene shows tolerance to loss-of-function variants based on population genetics data.

Summary from RefSeq, UniProt, Mechanism
Research Assistant →
0
Active trials
8
Pubs (1 yr)
11
P/LP submissions
0%
P/LP missense
0.84
LOEUF
Multiple*
Mechanism· predicted
Clinical SummarySLC16A6
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
11 unique Pathogenic / Likely Pathogenic· 76 VUS of 109 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.84LOEUF
pLI 0.002
Z-score 2.04
OE 0.44 (0.250.84)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
1.84Z-score
OE missense 0.70 (0.630.79)
211 obs / 300.9 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.44 (0.250.84)
00.351.4
Missense OE0.70 (0.630.79)
00.61.4
Synonymous OE1.05
01.21.6
LoF obs/exp: 7 / 15.7Missense obs/exp: 211 / 300.9Syn Z: -0.40
DN
0.79top 25%
GOF
0.83top 10%
LOF
0.2190th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

109 submitted variants in ClinVar

Classification Summary

Pathogenic10
Likely Pathogenic1
VUS76
Likely Benign14
Benign2
10
Pathogenic
1
Likely Pathogenic
76
VUS
14
Likely Benign
2
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
10
0
10
Likely Pathogenic
0
0
1
0
1
VUS
0
73
3
0
76
Likely Benign
0
10
0
4
14
Benign
0
0
0
2
2
Total083146103

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

SLC16A6 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →